Business Context and Reporting Period
SciSparc Ltd. (the "Company") filed Form 6-K on October 24, 2025, reporting the closing of a strategic transaction. The Company entered into an agreement on February 25, 2025, to sell its majority-owned subsidiary, MitoCareX Bio Ltd., to N2OFF, Inc. The transaction officially closed on October 20, 2025, upon satisfaction of all closing conditions.
Key Financial Metrics and Transaction Details
This filing details a specific asset sale rather than providing comprehensive periodic financial statements (e.g., revenue, EBITDA, or cash flow for the period). The financial consideration received by SciSparc for the sale of MitoCareX includes:
- Cash Consideration: $700,000 paid by N2OFF, Inc.
- Equity Consideration: 490,751 shares of N2OFF common stock, representing 16.75% of N2OFF on a fully-diluted basis.
- Asset Transferred: 100% of the fully-diluted share capital of MitoCareX Bio Ltd.
The filing text does not provide clear values for the Company's overall revenue, profit, operating cash flow, debt levels, or liquidity position for the reporting period.
Material Changes
The primary material change is the divestiture of MitoCareX Bio Ltd., which is no longer a subsidiary of SciSparc following the closing. The Company has transitioned from holding a majority stake in MitoCareX to holding a minority equity stake in N2OFF, Inc., alongside a cash infusion.
Outlook, Risks, and Management Commentary
Management highlighted that the transaction advances drug discovery for resistant cancers, specifically pancreatic and non-small cell lung cancer, through the N2OFF platform. The filing incorporates a press release detailing the strategic rationale. No specific forward-looking financial guidance, risk factors, or contingencies regarding future performance were explicitly detailed in the text of this specific Form 6-K, other than the successful execution of the sale.
Investor Verification Checklist
- Verify the fair market value of the 490,751 N2OFF shares received and their current trading status.
- Confirm the impact of the MitoCareX divestiture on SciSparc's consolidated balance sheet and future revenue streams.
- Review the full text of the Securities Purchase and Exchange Agreement for any earn-out provisions or future obligations not detailed in this summary.
- Assess the strategic fit of the remaining SciSparc portfolio following the exit from MitoCareX.